PATENT CLAIM ANALYSIS

Application Number: 16188238
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-03
Patent Classification: ["514", "485000"]

Abstract:
Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, salts, hydrates and solvates thereof, wherein R 1 , R 2 , R 3  and R 4  have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

Claim (Index 3):
A compound according to  claim 1  or  2  of Formula (Ib) wherein: R 7  is selected from the group consisting of \u2014C\u2261CH, \u2014CN, \u2014C(\u2550O)O\u2014R 6 , \u2014C(\u2550O)N(R 6 ) 2  and C 1 -C 4 alkyl optionally substituted with one or more substituents selected from the group consisting of \u2014C\u2261CH, \u2014CN, \u2014OH, C 1 -C 4 alkyloxy, \u2014C(\u2550O)O\u2014R 6 , \u2014C(\u2550O)N(R 6 ) 2 , \u2014N(R 6 ) 2 , \u2014NHC(\u2550O)\u2014R 6  and \u2014NHC(\u2550O)O\u2014R 6 ; Each R 6  independently represents hydrogen or C 1 -C 3 alkyl; and wherein Each R 8  independently represents hydrogen or C 1 -C 2 alkyl optionally substituted with OH.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 98.0
- Lexical Diversity: 1.30357
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14771448', '14782308', '15886766', '14424280', '14423963']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7530059364134946
- 35 USC 102 Novelty (BERT): 0.4593645368414293
- Combined Prediction Score: 0.723641796456288
- Mean Citation Score: 194.112602
- Max Citation Score: 202.6691
- Similarity Product: 198.60745913212293

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test